Puma Biotechnology

Puma’s controversial cancer drug secures FDA approval

After much speculation, FDA has given the green light to Puma's investigational breast cancer therapy neratinib (Nerlynx). Pivotal data had shown marginal benefits and a high rate of side effects, blurring the line between risk and reward.

By Juliet Preston

BioPharma, Pharma

There’s a therapeutic curveball heading for the FDA

To approve or not to approve, that is the question. Puma's investigational breast cancer drug could save lives, but is it worth the all-but-guaranteed side effects?

By Juliet Preston

Closing the Quality-Affordability Gap in Workplace Mental Health

In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.

By Stephanie Baum

Automation Didn’t Dehumanize Care. Bad Systems Did.

We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring.

By Michael Blackman, MD, MBA Chief Medical Officer, Greenway Health®

Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork

By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.

By Michael Blackman, MD, MBA Chief Medical Officer, Greenway Health®